1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Swedish Orphan Biovitrum AB (publ)
  6. News
  7. Summary
    SOBI   SE0000872095

SWEDISH ORPHAN BIOVITRUM AB (PUBL)

(SOBI)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Apellis Pharmaceuticals, Inc. and Swedish Orphan Biovitrum AB Announce EU Approval of Aspaveli® (Pegcetacoplan) for Treatment of PNH

12/15/2021 | 07:00am EDT

Apellis Pharmaceuticals, Inc. and Swedish Orphan Biovitrum AB (publ) announced that the European Commission (EC) has approved Aspaveli® (pegcetacoplan), the first and only targeted C3 therapy, for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH) who are anemic after treatment with a C5 inhibitor for at least three months. Based on the recommendation from the European Medicines Agency’s Committee for Orphan Medicinal Products, the EC determined that pegcetacoplan continues to meet the criteria for the orphan drug designation status granted in 2017 for the treatment of PNH. PNH is a rare, chronic and life-threatening blood disorder where uncontrolled complement activation leads to the destruction of oxygen-carrying red blood cells through intravascular hemolysis and extravascular hemolysis. Characterized by persistently low hemoglobin, PNH can result in frequent transfusions and debilitating symptoms such as severe fatigue caused by anemia. Despite improvements in hemolytic activity with C5 inhibitor treatment, approximately 72% of people with PNH treated with C5 inhibitors remain anemic, according to a retrospective and a cross-sectional study. The approval is based on the results from the head-to-head PEGASUS Phase 3 study, which evaluated the efficacy and safety of Aspaveli compared to eculizumab at 16 weeks in adults with PNH who had persistent anaemia despite treatment with eculizumab. The full safety and efficacy results were published in The New England Journal of Medicine in March 2021. Orphan drug designation is granted to therapies that treat a serious disease that affects fewer than five in 10,000 people in the EU and provide a significant benefit over existing treatments. Aspaveli will have market exclusivity based on orphan drug designation for PNH.


© S&P Capital IQ 2021
All news about SWEDISH ORPHAN BIOVITRUM AB (PUBL)
05/10Bulletin from Swedish Orphan Biovitrum (Sobi®)'s Annual General Meeting (AGM)
AQ
05/10Swedish Orphan Biovitrum AB Elects Bo Jesper Hansen as New Board Member
CI
04/28Swedish Orphan Biovitrum AB Reports Earnings Results for the First Quarter Ended March ..
CI
04/28TRANSCRIPT : Swedish Orphan Biovitrum AB, Q1 2022 Earnings Call, Apr 28, 2022
CI
04/28Swedish Drugmaker Sobi Confirms FY22 Revenue Outlook After Q1 Growth
MT
04/28Drugmaker Sobi books profit fall on restructuring, Russia
RE
04/28Sobi publishes Q1 2022 report
AQ
04/28Swedish Orphan Biovitrum AB Provides Earnings Guidance for the Year 2022
CI
04/20INVITATION : Sobi's Q1 2022 report
AQ
04/06Swedish Orphan Biovitrum AB - Annual and Sustainability Report 2021
AQ
More news
Analyst Recommendations on SWEDISH ORPHAN BIOVITRUM AB (PUBL)
More recommendations
Financials
Sales 2022 17 553 M 1 784 M 1 784 M
Net income 2022 2 377 M 242 M 242 M
Net Debt 2022 6 950 M 706 M 706 M
P/E ratio 2022 26,7x
Yield 2022 -
Capitalization 62 101 M 6 312 M 6 312 M
EV / Sales 2022 3,93x
EV / Sales 2023 3,44x
Nbr of Employees 1 569
Free-Float 58,8%
Chart SWEDISH ORPHAN BIOVITRUM AB (PUBL)
Duration : Period :
Swedish Orphan Biovitrum AB (publ) Technical Analysis Chart | SOBI | SE0000872095 | MarketScreener
Technical analysis trends SWEDISH ORPHAN BIOVITRUM AB (PUBL)
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Last Close Price 210,40 SEK
Average target price 245,88 SEK
Spread / Average Target 16,9%
EPS Revisions
Managers and Directors
Guido Oelkers President & Chief Executive Officer
Henrik Stenqvist Chief Financial Officer
Sven Håkan Björklund Chairman
Anne Marie de Jonge Schuermans Head-Technical Operations & Senior Vice President
Sven Anders Ullman Chief Medical Officer, Head-Research & Development
Sector and Competitors